Skip to main content
SpringerLink
Log in

Insulin Glargine

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Insulin glargine is an extended-action biosynthetic human insulin. It precipitates in the neutral environment of subcutaneous tissue and is thus gradually absorbed into the bloodstream. The addition of small amounts of zinc to the formulation further delays absorption.

  • ▴ In small euglycaemic clamp studies, the onset of action of insulin glargine was shown to be later, the duration of action longer and the time-action profile flatter than that of Neutral Protamine Hagedorn (NPH) insulin inpatients with type 1 diabetes mellitus and healthy volunteers.

  • ▴ Four large clinical trials of up to 28 weeks’ duration have shown that a single bedtime dose of insulin glargine, in combination with preprandial short-acting insulin, is as effective or more effective than once or twice daily NPH plus short-acting insulin in improving glycaemic control in patients with type 1 diabetes mellitus.

  • ▴ In 3 large comparative trials, insulin glargine decreased glycosylated haemoglobin and/or fasting blood glucose levels to a similar extent to that seen with NPH insulin in patients with insulin-dependent or non-insulin-dependent type 2 diabetes mellitus, either as monotherapy or in combination with oral hypoglycaemic agents.

  • ▴ Insulin glargine appears to be well tolerated. A lower incidence of hypoglycaemia, especially at night, was reported in most trials with insulin glargine when compared with NPH insulin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mandrap-Poulsen T. Diabetes. BMJ 1998 Apr 18; 316: 1221–5

    Article  Google Scholar 

  2. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999 Mar; 22 Suppl. 2: 109–13

    Google Scholar 

  3. Home P. Insulin glargine: the first clinically useful extendedacting insulin in half a century ? Expert Opin Invest Drug 1999 Mar; 8: 307–14

    Article  CAS  Google Scholar 

  4. Berti L, Seffer E, Scipke G, et al. Human insulin analog HOE901: characteristics of receptor binding and tyrosine kinase activation [abstract]. Diabetes 1995 May; 44 Suppl. 1: 243

    Google Scholar 

  5. Bähr M, Kolter T, Scipke G, et al. Growth promoting and metabolic activity of the human insulin analogue [Gly(A21), Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997 Feb 12; 320: 259–65

    Article  PubMed  Google Scholar 

  6. Scipke G, Berchthold H, Geisen K, et al. HOE901 — a new insulin with prolonged action [abstract]. Eur J Endocrinol 1995 Apr; 132 Suppl. 1: 25

    Google Scholar 

  7. Linkeschowa R, Heise T, Rave K, et al. Time-action profile of the long-acting insulin analogue HOE901 [abstract]. Diabetes 1999 May; 48 Suppl. 1: 97

    Google Scholar 

  8. Soon PC, Matthews DR, Rosskamp R, et al. 24h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology [abstract]. Diabetes 1997 May; 46 Suppl. 1: 161

    Google Scholar 

  9. Dreyer M, Pein M, Schmidt C, et al. Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31,B32)-humaninsulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6–11; Kobe, Japan, 252

  10. Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 comopared to NPH and ultralente human insulins using the euglycaemic clamp technique [Abstract no. 882]. Diabetologia 1999; 42 Suppl. 1: A235

    Google Scholar 

  11. Lepore M, Kurzhals R, Pampanelli S, et al. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE1) of T1DM [abstract]. Diabetes 1999 May; 48 Suppl. 1: 97

    Google Scholar 

  12. Coates PA, Mukherjee S, Luzio S, et al. Pharmacokinetics of a long-acting human insulin analogue (HOE901) in healthy subjects [abstract]. Diabetes 1995 May; 44 Suppl. 1: 130A

    Google Scholar 

  13. Luzio SD, Owens D, Evans M, et al. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects [abstract]. Diabetes 1999 May; 48 Suppl. 1: 111

    Google Scholar 

  14. Ratner RE, Hirsch IB, Mecca TE, et al. Efficacy and safety of insulin glargine in subjects with type 1 diabetes: a 28 week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1999 May; 48 Suppl. 1: 120

    Google Scholar 

  15. Rosenstock J, Park G, Zimmerman J. Efficacy and safety of HOE 901 in patients with type 1 DM: a four-week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1998 May; 47 Suppl. 1: 92

    Google Scholar 

  16. Pieber TR, Eugène-Jolchine I, Derobert E. Efficacy and safety of HOE901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial [abstract]. Diabetologia 1998 Aug; 41 Suppl. 1: 49

    Google Scholar 

  17. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes [abstract]. Diabetes 1998 May; 47 Suppl. 1: 103

    Google Scholar 

  18. Rosenstock J, Schwartz S, Clark C, et al. Efficacy and safety of HOE 901 (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1999 May; 48 Suppl. 1: 100

    Google Scholar 

  19. Matthews DR, Pfeiffer C, Multicentre HOE901 Research Group. Comparative clinical trial of a new long-acting insulin (HOE901) vs protamine insulin demonstrates less nocturnal hypoglycaemia [abstract]. Diabetes 1998 May; 47 Suppl. 1: 101

    Google Scholar 

  20. Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type I diabetes mellitus without increasing the risk of hypoglycaemia [abstract no. 883]. Diabetologia 1999; 42 Suppl. 1: A235

    Google Scholar 

  21. Garg S, Gerard L, Pennington M, et al. Efficacy of the new long acting insulin analog (HOE901) on fasting glucose values in IDDM [abstract]. Diabetes 1998 May; 47 Suppl. 1: 359

    Google Scholar 

  22. Talaulicar M, Willms B, Rosskamp R. Efficacy of HOE901 following subcutaneous injection for four days in type I diabetic subjects [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6–11; Kobe, Japan, 247

  23. Pieber TR, Eugène-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type I diabetes. Diabetes Care 2000; 23(2): 157–62

    Article  PubMed  CAS  Google Scholar 

  24. Bradley C, Witthaus E, Stewart J. Treatment satisfaction and psychological well-being in patients with type 1 diabetes, treated with a new long-acting insulin, insulin glargine [abstract]. Diabetes 1999 May; 48 Suppl. 1: 353

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Peter S. Gillies, David P. Figgitt & Harriet M. Lamb

Authors
  1. Peter S. Gillies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Figgitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harriet M. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Figgitt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gillies, P.S., Figgitt, D.P. & Lamb, H.M. Insulin Glargine. Drugs 59, 253–260 (2000). https://doi.org/10.2165/00003495-200059020-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059020-00009

Keywords

Search

Navigation